Renaissance Technologies - CATABASIS PHARMACEUTICALS IN ownership

CATABASIS PHARMACEUTICALS IN's ticker is CATB and the CUSIP is 14875P107. A total of 23 filers reported holding CATABASIS PHARMACEUTICALS IN in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
Renaissance Technologies ownership history of CATABASIS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2018$363,000
-85.6%
453,740
-74.6%
0.00%
-100.0%
Q2 2018$2,524,000
+46.5%
1,787,100
+87.7%
0.00%
-50.0%
Q1 2018$1,723,000
+146.8%
952,200
+103.2%
0.00%
+100.0%
Q4 2017$698,000
+87.6%
468,700
+167.2%
0.00%
Q3 2017$372,000
+131.1%
175,400
+53.2%
0.00%
Q2 2017$161,000
+51.9%
114,500
+73.2%
0.00%
Q1 2017$106,00066,1000.00%
Other shareholders
CATABASIS PHARMACEUTICALS IN shareholders Q1 2017
NameSharesValueWeighting ↓
SV Health Investors, LLC 2,857,667$4,572,0005.05%
Clarus Ventures, LLC 2,752,488$4,404,0003.28%
SPHERA FUNDS MANAGEMENT LTD. 388,030$621,0000.12%
Rhenman & Partners Asset Management AB 310,756$497,0000.08%
BOSTON FAMILY OFFICE LLC 24,467$39,0000.01%
OPPENHEIMER & CO INC 90,000$144,0000.00%
Alyeska Investment Group, L.P. 221,281$354,0000.00%
A.R.T. Advisors, LLC 46,747$74,0000.00%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 101,347$162,0000.00%
Acrospire Investment Management LLC 680$1,0000.00%
View complete list of CATABASIS PHARMACEUTICALS IN shareholders